These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 20109144)

  • 21. Dopamine D2 receptor occupancy predicts catalepsy and the suppression of conditioned avoidance response behavior in rats.
    Wadenberg ML; Kapur S; Soliman A; Jones C; Vaccarino F
    Psychopharmacology (Berl); 2000 Jul; 150(4):422-9. PubMed ID: 10958084
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Contrasting loxapine to its isomer isoloxapine--the critical role of in vivo D2 blockade in determining atypicality.
    Natesan S; Vanderspek S; Nobrega JN; McClelland RA; Kapur S
    Schizophr Res; 2005 Sep; 77(2-3):189-99. PubMed ID: 15925489
    [TBL] [Abstract][Full Text] [Related]  

  • 23. F15063, a compound with D2/D3 antagonist, 5-HT 1A agonist and D4 partial agonist properties. III. Activity in models of cognition and negative symptoms.
    Depoortère R; Auclair AL; Bardin L; Bruins Slot L; Kleven MS; Colpaert F; Vacher B; Newman-Tancredi A
    Br J Pharmacol; 2007 May; 151(2):266-77. PubMed ID: 17375085
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anticholinergic drugs potentiate dopamine D1 but not D2 antagonists on a conditioned avoidance task in rats.
    Iorio LC; Cohen M; Coffin VL
    J Pharmacol Exp Ther; 1991 Jul; 258(1):118-23. PubMed ID: 1830098
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Atypical antipsychotics: mechanism of action.
    Seeman P
    Can J Psychiatry; 2002 Feb; 47(1):27-38. PubMed ID: 11873706
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PD 158771, a potential antipsychotic agent with D2/D3 partial agonist and 5-HT(1A) agonist actions. II. Preclinical behavioral effects.
    Corbin AE; Meltzer LT; Ninteman FW; Wiley JN; Christoffersen CL; Wustrow DJ; Wise LD; Pugsley TA; Heffner TG
    Neuropharmacology; 2000 Apr; 39(7):1211-21. PubMed ID: 10760363
    [TBL] [Abstract][Full Text] [Related]  

  • 27. "Breakthrough" dopamine supersensitivity during ongoing antipsychotic treatment leads to treatment failure over time.
    Samaha AN; Seeman P; Stewart J; Rajabi H; Kapur S
    J Neurosci; 2007 Mar; 27(11):2979-86. PubMed ID: 17360921
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Repeated administration of aripiprazole produces a sensitization effect in the suppression of avoidance responding and phencyclidine-induced hyperlocomotion and increases D2 receptor-mediated behavioral function.
    Gao J; Qin R; Li M
    J Psychopharmacol; 2015 Apr; 29(4):390-400. PubMed ID: 25586399
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Brexpiprazole II: antipsychotic-like and procognitive effects of a novel serotonin-dopamine activity modulator.
    Maeda K; Lerdrup L; Sugino H; Akazawa H; Amada N; McQuade RD; Stensbøl TB; Bundgaard C; Arnt J; Kikuchi T
    J Pharmacol Exp Ther; 2014 Sep; 350(3):605-14. PubMed ID: 24947464
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Enhanced efficacy of both typical and atypical antipsychotic drugs by adjunctive alpha2 adrenoceptor blockade: experimental evidence.
    Wadenberg ML; Wiker C; Svensson TH
    Int J Neuropsychopharmacol; 2007 Apr; 10(2):191-202. PubMed ID: 16707032
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dopamine D2 receptors as treatment targets in schizophrenia.
    Seeman P
    Clin Schizophr Relat Psychoses; 2010 Apr; 4(1):56-73. PubMed ID: 20643630
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Enhanced cortical dopamine output and antipsychotic-like effects of raclopride by alpha2 adrenoceptor blockade.
    Hertel P; Fagerquist MV; Svensson TH
    Science; 1999 Oct; 286(5437):105-7. PubMed ID: 10506554
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Antipsychotics with no dopamine receptor blockade; promise or hype?].
    Vinkers CH
    Ned Tijdschr Geneeskd; 2020 Dec; 164():. PubMed ID: 33332053
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The dopamine stabilizers (S)-(-)-(3-methanesulfonyl-phenyl)-1-propyl-piperidine [(-)-OSU6162] and 4-(3-methanesulfonylphenyl)-1-propyl-piperidine (ACR16) show high in vivo D2 receptor occupancy, antipsychotic-like efficacy, and low potential for motor side effects in the rat.
    Natesan S; Svensson KA; Reckless GE; Nobrega JN; Barlow KB; Johansson AM; Kapur S
    J Pharmacol Exp Ther; 2006 Aug; 318(2):810-8. PubMed ID: 16648369
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antagonist and partial agonist at the dopamine D2 receptors in drug-naïve and non-drug-naïve schizophrenia: a randomized, controlled trial.
    Takekita Y; Fabbri C; Kato M; Nonen S; Sakai S; Sunada N; Koshikawa Y; Wakeno M; Okugawa G; Kinoshita T; Serretti A
    Eur Arch Psychiatry Clin Neurosci; 2015 Oct; 265(7):579-88. PubMed ID: 26016467
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Noradrenaline reuptake inhibition enhances the antipsychotic-like effect of raclopride and potentiates D2-blockage-induced dopamine release in the medial prefrontal cortex of the rat.
    Linnér L; Wiker C; Wadenberg ML; Schalling M; Svensson TH
    Neuropsychopharmacology; 2002 Nov; 27(5):691-8. PubMed ID: 12431844
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Apomorphine-induced emesis in dogs: differential sensitivity to established and novel dopamine D2/5-HT(1A) antipsychotic compounds.
    Depoortère R; Barret-Grévoz C; Bardin L; Newman-Tancredi A
    Eur J Pharmacol; 2008 Nov; 597(1-3):34-8. PubMed ID: 18773888
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Alpha-adrenoceptor modulation hypothesis of antipsychotic atypicality.
    Svensson TH
    Prog Neuropsychopharmacol Biol Psychiatry; 2003 Oct; 27(7):1145-58. PubMed ID: 14642973
    [TBL] [Abstract][Full Text] [Related]  

  • 39. DuP 734 [1-(cyclopropylmethyl)-4-(2'(4''-fluorophenyl)-2'- oxoethyl)piperidine HBr], a potential antipsychotic agent: preclinical behavioral effects.
    Cook L; Tam SW; Rohrbach KW
    J Pharmacol Exp Ther; 1992 Dec; 263(3):1159-66. PubMed ID: 1361571
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CI-943, a potential antipsychotic agent. I. Preclinical behavioral effects.
    Heffner TG; Downs DA; Meltzer LT; Wiley JN; Williams AE
    J Pharmacol Exp Ther; 1989 Oct; 251(1):105-12. PubMed ID: 2571712
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.